KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Leerink Partners Reiterates Outperform Rating on Kalvista Pharmaceuticals Inc (KALV)
July 10, 2025 10:29 AM EDTLeerink Partners analyst Joseph Schwartz reiterated an Outperform rating and $20.00 price target on Kalvista Pharmaceuticals Inc (NASDAQ: KALV).
The analyst comments "We are updating our model following the disclosure of KALV's F4Q25 financial results and corporate update; the US launch for Ekterly is underway, while additional regulatory reviews are under review. As disclosed earlier this week (here), the FDA approved Ekterly (sebetralstat) as the first and only on-demand treatment for hereditary angioedema (HAE) attacks. Ekterly received... More
